Evommune, Inc. (EVMN)

Market Cap	592.23M
Revenue (ttm)	13.00M
Net Income (ttm)	-62.82M
Shares Out	30.08M
EPS (ttm)	-4.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	265,155
Open	19.96
Previous Close	19.61
Day's Range	19.45 - 20.54
52-Week Range	16.70 - 24.03
Beta	n/a
Analysts	Buy
Price Target	39.33 (+99.75%)
Earnings Date	Dec 11, 2025

About EVMN

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2025
• Employees: 45
• Stock Exchange: NYSE
• Ticker Symbol: EVMN
• Website: https://www.evommune.com

Financial Performance

Financial numbers in USD

Analyst Summary

According to 5 analysts, the average rating for EVMN stock is "Buy." The 12-month stock price target is $39.33, which is an increase of 99.75% from the latest price.

Price Target

$39.33

(99.75% upside)

Analyst Consensus: Buy